Handel Cytori Therapeutics - PSTV CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.06 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Nøglestatistikker
| Tidligere luk* | 0.38 |
| Åben* | 0.38 |
| 1-Års Ændring* | -60% |
| Dagens Spænd* | 0.37 - 0.38 |
| 52-Ugers Spænd | 0.27-1.20 |
| Gennemsnitlig Volumen (10 dage) | 205.82K |
| Gennemsnitlig Volumen (3 måneder) | 6.41M |
| Market Cap | 9.71M |
| P/E-forhold | -100.00K |
| Udestående aktier | 35.42M |
| Omsætning | 224.00K |
| EPS | -0.79 |
| Dividend (Udbytte %) | N/A |
| Beta | 0.42 |
| Næste indtjeningsopgørelse | Apr 19, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Feb 23, 2023 | 0.37 | -0.01 | -2.63% | 0.38 | 0.38 | 0.37 |
| Feb 22, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
| Feb 8, 2023 | 0.37 | -0.01 | -2.63% | 0.38 | 0.38 | 0.37 |
| Feb 6, 2023 | 0.38 | -0.01 | -2.56% | 0.39 | 0.39 | 0.38 |
| Feb 3, 2023 | 0.39 | 0.00 | 0.00% | 0.39 | 0.39 | 0.39 |
| Feb 2, 2023 | 0.39 | 0.00 | 0.00% | 0.39 | 0.40 | 0.38 |
| Feb 1, 2023 | 0.38 | -0.04 | -9.52% | 0.42 | 0.42 | 0.38 |
| Jan 31, 2023 | 0.40 | -0.02 | -4.76% | 0.42 | 0.42 | 0.39 |
| Jan 30, 2023 | 0.43 | 0.01 | 2.38% | 0.42 | 0.44 | 0.42 |
| Jan 27, 2023 | 0.42 | 0.01 | 2.44% | 0.41 | 0.42 | 0.40 |
| Jan 26, 2023 | 0.41 | 0.00 | 0.00% | 0.41 | 0.42 | 0.41 |
| Jan 25, 2023 | 0.41 | 0.01 | 2.50% | 0.40 | 0.42 | 0.40 |
| Jan 24, 2023 | 0.41 | 0.00 | 0.00% | 0.41 | 0.41 | 0.41 |
| Jan 23, 2023 | 0.41 | -0.01 | -2.38% | 0.42 | 0.43 | 0.41 |
| Jan 20, 2023 | 0.41 | -0.01 | -2.38% | 0.42 | 0.43 | 0.40 |
| Jan 19, 2023 | 0.42 | 0.01 | 2.44% | 0.41 | 0.42 | 0.40 |
| Jan 18, 2023 | 0.42 | -0.03 | -6.67% | 0.45 | 0.45 | 0.40 |
| Jan 17, 2023 | 0.45 | 0.00 | 0.00% | 0.45 | 0.45 | 0.43 |
| Jan 13, 2023 | 0.45 | 0.07 | 18.42% | 0.38 | 0.45 | 0.38 |
| Jan 9, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Cytori Therapeutics Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| No events scheduled | ||
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0.303 | 6.998 | 6.654 | 6.411 |
| Omsætning | 0 | 0.303 | 6.998 | 6.654 | 6.411 |
| Kost af omsætning, Total | 2.373 | 2.543 | |||
| Bruttofortjeneste | 4.281 | 3.868 | |||
| Totale Driftsudgifter | 12.492 | 9.887 | 10.655 | 19.352 | 27.094 |
| Salgs/Generelle/Admin. Udgifter, Total | 6.853 | 6.406 | 5.29 | 8.357 | 11.187 |
| Forskning & Udvikling | 5.323 | 2.7 | 5.365 | 8.622 | 11.678 |
| Renteudgift (Indkomst) - Netto Drift | |||||
| Usædvanlig Udgift (Indkomst) | 0.316 | 0.781 | 0 | 1.686 | |
| Driftsindtægter | -12.492 | -9.584 | -3.657 | -12.698 | -20.683 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -0.907 | 1.343 | 1.607 | 0.354 | -2.016 |
| Andre, Netto | 0 | -1.233 | -0.29 | 0.013 | |
| Netto Indkomst Før Skat | -13.399 | -8.241 | -3.283 | -12.634 | -22.686 |
| Netto Indkomst Efter Skat | -13.399 | -8.241 | -3.283 | -12.634 | -22.686 |
| Netto Indkomst Før Ekstra Ting | -13.399 | -8.241 | -3.283 | -12.634 | -22.686 |
| Netto Indkomst | -13.399 | -8.241 | -10.887 | -12.634 | -22.686 |
| Total Adjustments to Net Income | 0 | -0.554 | -2.487 | -3.977 | |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -13.399 | -8.241 | -3.837 | -15.121 | -26.663 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -13.399 | -8.241 | -11.441 | -15.121 | -26.663 |
| Fortyndet Netto Indkomst | -13.399 | -8.241 | -11.441 | -15.121 | -26.663 |
| Fortyndet Vægtet Gennemsnit Aktier | 12.0892 | 4.42784 | 1.38401 | 0.17385 | 0.06478 |
| Fortyndet EPS Uden Ekstraordinære Ting | -1.10835 | -1.86118 | -2.77237 | -86.9768 | -411.595 |
| Fortyndet Normaliseret EPS | -1.08221 | -1.6848 | -2.77237 | -86.9768 | -385.569 |
| Totale Ekstraordinære Ting | 0 | -7.604 | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Omsætning | 0 | 0 | 0 | 0 | |
| Totale Driftsudgifter | 3.926 | 3.939 | 3.499 | 2.575 | 2.479 |
| Salgs/Generelle/Admin. Udgifter, Total | 2.141 | 2.042 | 1.99 | 1.469 | 1.352 |
| Forskning & Udvikling | 1.785 | 1.599 | 1.491 | 1.106 | 1.127 |
| Driftsindtægter | -3.926 | -3.939 | -3.499 | -2.575 | -2.479 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -0.19 | -0.216 | -0.225 | -0.225 | -0.241 |
| Netto Indkomst Før Skat | -4.116 | -4.155 | -3.724 | -2.8 | -2.72 |
| Netto Indkomst Efter Skat | -4.116 | -4.155 | -3.724 | -2.8 | -2.72 |
| Netto Indkomst Før Ekstra Ting | -4.116 | -4.155 | -3.724 | -2.8 | -2.72 |
| Netto Indkomst | -4.116 | -4.155 | -3.724 | -2.8 | -2.72 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -4.116 | -4.155 | -3.724 | -2.8 | -2.72 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -4.116 | -4.155 | -3.724 | -2.8 | -2.72 |
| Fortyndet Netto Indkomst | -4.116 | -4.155 | -3.724 | -2.8 | -2.72 |
| Fortyndet Vægtet Gennemsnit Aktier | 21.5071 | 15.4729 | 13.2642 | 11.2968 | 8.2679 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.19138 | -0.26853 | -0.28076 | -0.24786 | -0.32898 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Fortyndet Normaliseret EPS | -0.19138 | -0.24927 | -0.2794 | -0.24786 | -0.32898 |
| Usædvanlig Udgift (Indkomst) | 0.298 | 0.018 | 0 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 19.724 | 9.175 | 19.825 | 9.648 | 14.864 |
| Likvider og Kortsigtede Investeringer | 18.4 | 8.346 | 17.552 | 5.261 | 9.55 |
| Likvider & Lignende | 18.4 | 8.346 | 17.552 | 5.261 | 9.55 |
| Totale Tilgodehavender, Netto | 0 | 1.313 | 0.178 | 0.145 | |
| Accounts Receivable - Trade, Net | 0 | 1.169 | 0.178 | 0.145 | |
| Total Inventory | 0 | 0.107 | 0.107 | 3.183 | |
| Other Current Assets, Total | 0.007 | 0.059 | 0.04 | 4.102 | 1.986 |
| Total Assets | 21.981 | 12.105 | 23.229 | 23.991 | 31.615 |
| Property/Plant/Equipment, Total - Net | 1.818 | 2.456 | 2.96 | 2.299 | 3.052 |
| Goodwill, Net | 0.372 | 0.372 | 0.372 | 0.372 | 3.922 |
| Intangibles, Net | 0.051 | 0.086 | 7.207 | ||
| Other Long Term Assets, Total | 0.016 | 0.016 | 0.072 | 11.672 | 2.57 |
| Total Current Liabilities | 5.87 | 8.539 | 14.486 | 17.559 | 18.414 |
| Payable/Accrued | 0.245 | 2.777 | 4.79 | ||
| Notes Payable/Short Term Debt | 1.608 | 6.335 | 0 | 14.202 | 13.624 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.01 | 11.18 | ||
| Total Liabilities | 11.145 | 9.074 | 22.069 | 18.766 | 18.615 |
| Total Long Term Debt | 5.005 | 0 | 0.008 | 0 | 0 |
| Long Term Debt | 5.005 | 0 | |||
| Other Liabilities, Total | 0.27 | 0.535 | 7.575 | 1.207 | 0.201 |
| Total Equity | 10.836 | 3.031 | 1.16 | 5.225 | 13 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Common Stock | 0.016 | 0.007 | 0.004 | 0 | 0.058 |
| Additional Paid-In Capital | 457.73 | 436.535 | 426.426 | 418.39 | 413.304 |
| Retained Earnings (Accumulated Deficit) | -446.91 | -433.511 | -425.27 | -414.383 | -401.749 |
| Other Equity, Total | 0 | 1.218 | 1.387 | ||
| Total Liabilities & Shareholders’ Equity | 21.981 | 12.105 | 23.229 | 23.991 | 31.615 |
| Total Common Shares Outstanding | 15.51 | 6.74903 | 3.88059 | 0.29661 | 0.11565 |
| Property/Plant/Equipment, Total - Gross | 3.233 | 3.843 | 3.981 | 0 | |
| Accrued Expenses | 1.529 | 1.137 | 2.973 | 0 | |
| Other Current Liabilities, Total | 0.122 | 0.023 | 0.006 | 0.58 | |
| Prepaid Expenses | 1.317 | 0.77 | 0.813 | ||
| Accumulated Depreciation, Total | -1.415 | -1.387 | -1.021 | ||
| Accounts Payable | 2.611 | 0.789 | 0.327 | ||
| Capital Lease Obligations | 0 | 0.008 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 22.104 | 19.724 | 22.097 | 18.001 | 15.446 |
| Likvider og Kortsigtede Investeringer | 21.239 | 18.4 | 21.28 | 17.161 | 14.447 |
| Likvider & Lignende | 21.239 | 18.4 | 21.28 | 17.161 | 14.447 |
| Other Current Assets, Total | 0.865 | 1.324 | 0.817 | 0.84 | 0.999 |
| Total Assets | 24.516 | 21.981 | 24.75 | 20.834 | 18.336 |
| Property/Plant/Equipment, Total - Net | 1.874 | 1.818 | 2.205 | 2.376 | 2.425 |
| Goodwill, Net | 0.372 | 0.372 | 0.372 | 0.372 | 0.372 |
| Intangibles, Net | 0.15 | 0.051 | 0.06 | 0.069 | 0.077 |
| Other Long Term Assets, Total | 0.016 | 0.016 | 0.016 | 0.016 | 0.016 |
| Total Current Liabilities | 4.921 | 5.87 | 9.488 | 8.354 | 8.315 |
| Payable/Accrued | 3.203 | 4.151 | 2.63 | 1.609 | 1.713 |
| Accrued Expenses | 0.11 | 0.111 | 0.106 | 0.127 | 0.113 |
| Notes Payable/Short Term Debt | 1.608 | 1.608 | 6.752 | 6.618 | 6.486 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.003 | |||
| Total Liabilities | 9.874 | 11.145 | 9.995 | 8.889 | 8.823 |
| Total Long Term Debt | 4.718 | 5.005 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | ||||
| Other Liabilities, Total | 0.235 | 0.27 | 0.507 | 0.535 | 0.508 |
| Total Equity | 14.642 | 10.836 | 14.755 | 11.945 | 9.513 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Common Stock | 0.022 | 0.016 | 0.015 | 0.012 | 0.01 |
| Additional Paid-In Capital | 465.646 | 457.73 | 457.495 | 450.964 | 445.734 |
| Retained Earnings (Accumulated Deficit) | -451.026 | -446.91 | -442.755 | -439.031 | -436.231 |
| Total Liabilities & Shareholders’ Equity | 24.516 | 21.981 | 24.75 | 20.834 | 18.336 |
| Total Common Shares Outstanding | 22.1976 | 15.51 | 15.36 | 12.0875 | 10.1805 |
| Long Term Debt | 4.718 | 5.005 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netto indkomst/Startlinje | -13.399 | -8.241 | -10.887 | -12.634 | -22.686 |
| Likvider Fra Driftsaktiviteter | -10.28 | -8.434 | -5.906 | -11.975 | -18.128 |
| Likvider Fra Driftsaktiviteter | 0.395 | 0.366 | 0.896 | 2.004 | 2.151 |
| Ikke-Likvide Ting | 1.486 | -0.678 | 5.023 | -0.313 | 3.444 |
| Likvid Rente Betalt | 0.388 | 0.567 | 1.188 | 1.331 | 1.364 |
| Ændringer i Driftskapital | 1.238 | 0.119 | -0.938 | -1.032 | -1.037 |
| Likvider fra Investeringsaktiviteter | -0.082 | -0.493 | 5.57 | -0.133 | -1.383 |
| Kapitaludgifter | -0.144 | -0.493 | -0.067 | -0.133 | -1.496 |
| Andre Investerings-Cash-Flow-Ting, Total | 0.062 | 0 | 5.637 | 0 | 0.113 |
| Likvider fra Financieringsaktiviteter | 20.416 | -0.319 | 12.631 | 7.168 | 16.815 |
| Financiering af Cash-Flow-Ting | 0 | -1.598 | -2.078 | ||
| Total Cash Dividends Paid | |||||
| Udstedelse (Pensionering) af Aktier, Netto | 20.692 | 5.105 | 16.454 | 8.766 | 23.613 |
| Udstedelse (Pensionering) af Gæld, Netto | -0.276 | -5.424 | -3.823 | 0 | -4.72 |
| Udenlandsk Børs Effekter | 0 | -0.004 | 0.016 | 0.011 | |
| Netto Ændring i Likviditet | 10.054 | -9.246 | 12.291 | -4.924 | -2.685 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -4.116 | -13.399 | -9.244 | -5.52 | -2.72 |
| Cash From Operating Activities | -3.876 | -10.28 | -7.656 | -5.405 | -3.006 |
| Cash From Operating Activities | 0.147 | 0.395 | 0.266 | 0.179 | 0.088 |
| Non-Cash Items | 0.284 | 1.486 | 0.892 | 0.53 | 0.257 |
| Cash Interest Paid | 0.087 | 0.388 | 0.292 | 0.29 | 0.096 |
| Changes in Working Capital | -0.191 | 1.238 | 0.43 | -0.594 | -0.631 |
| Cash From Investing Activities | -0.577 | -0.082 | -0.084 | -0.08 | -0.084 |
| Capital Expenditures | -0.327 | -0.144 | -0.134 | -0.08 | -0.084 |
| Cash From Financing Activities | 7.292 | 20.416 | 20.674 | 14.3 | 9.191 |
| Issuance (Retirement) of Stock, Net | 7.694 | 20.692 | 20.682 | 14.308 | 9.197 |
| Issuance (Retirement) of Debt, Net | -0.402 | -0.276 | -0.008 | -0.008 | -0.006 |
| Net Change in Cash | 2.839 | 10.054 | 12.934 | 8.815 | 6.101 |
| Other Investing Cash Flow Items, Total | -0.25 | 0.062 | 0.05 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.0859 | 1092953 | 385 | 2022-12-31 | LOW |
| Parkman Healthcare Partners LLC | Hedge Fund | 1.6474 | 583467 | -741558 | 2022-12-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7286 | 258052 | -385 | 2022-12-31 | LOW |
| Schonfeld Strategic Advisors LLC | Hedge Fund | 0.5376 | 190400 | 190400 | 2022-12-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 0.3865 | 136903 | 124500 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2948 | 104427 | 0 | 2022-12-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 0.2376 | 84147 | -22260 | 2022-12-31 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 0.2213 | 78370 | 7470 | 2022-12-31 | HIGH |
| Petersen (Gregory B) | Individual Investor | 0.1765 | 62500 | 0 | 2023-02-23 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.0972 | 34414 | 0 | 2022-12-31 | LOW |
| Great Valley Advisor Group, Inc. | Investment Advisor | 0.0949 | 33600 | 0 | 2022-12-31 | MED |
| Hedrick (Marc H) | Individual Investor | 0.0948 | 33580 | 0 | 2023-02-23 | LOW |
| Creative Planning, Inc. | Investment Advisor/Hedge Fund | 0.0947 | 33539 | 0 | 2022-12-31 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.0906 | 32089 | 0 | 2022-12-31 | LOW |
| B. Riley Wealth Advisors, Inc. | Investment Advisor | 0.0706 | 25001 | 25001 | 2022-12-31 | MED |
| UBS Financial Services, Inc. | Investment Advisor | 0.0537 | 19003 | 2795 | 2022-12-31 | LOW |
| Clowes (Howard) | Individual Investor | 0.0508 | 18000 | 0 | 2023-02-23 | MED |
| Virtu Americas LLC | Research Firm | 0.0385 | 13647 | 13647 | 2022-12-31 | HIGH |
| Sims Andrew (John Hugh MacIntyre) | Individual Investor | 0.0345 | 12230 | 0 | 2023-02-23 | LOW |
| Warberg Asset Management LLC | Hedge Fund | 0.0282 | 10000 | 0 | 2022-12-31 | HIGH |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Cytori Therapeutics Company profile
Om Cytori Therapeutics
Plus Therapeutics, Inc. er et lægemiddelfirma i den kliniske fase. Virksomheden fokuserer på at udvikle behandlinger til patienter, der kæmper mod kræft. Selskabet tilbyder en nanoteknologisk platform til at omformulere og forbedre de mest effektive kemoterapeutika for at give patienter og sundhedsudbydere fordele. Selskabet er fokuseret på at udvikle generiske onkologiske lægemidler, der imødekommer uopfyldte medicinske og markedsmæssige behov. Selskabets førende produktkandidat, DocePLUS, er en albumin-stabiliseret PEG-stabiliseret liposomal liposomal formulering af docetaxel. DocePLUS er udviklet til behandling af patienter med småcellet lungekræft (SCLC). Selskabet er også ved at udvikle DoxoPLUS, som er en generisk PEGylated liposomal formulering af doxorubicin. DoxoPLUS er udviklet til behandling af brystkræft, kræft i æggestokkene, multipel myelom og Kaposi's sarkom. Virksomheden fokuserer også på at udvikle Rhenium-186 NanoLiposome (186RNL) til behandling af tilbagevendende glioblastom - en sjælden, uhelbredelig og dødelig sygdom.
| Industry: | Biotechnology & Medical Research (NEC) |
4200 Marathon Blvd Ste 200
AUSTIN
TEXAS 78756-3433
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com